Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia

BACKGROUND: Imatinib, a first-generation tyrosine kinase inhibitor (TKI), and the newer second-generation TKIs have dramatically improved outcomes for patients with chronic myelogenous leukemia (CML). A previous model estimated the potential cost-savings over the next 2 years after the loss of paten...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am Health Drug Benefits
Asıl Yazarlar: Campbell, David, Blazer, Marlo, Bloudek, Lisa, Brokars, John, Makenbaeva, Dinara
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Engage Healthcare Communications, LLC 2019
Konular:
Business
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6996618/
https://ncbi.nlm.nih.gov/pubmed/32055281
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller